Skip to main content
Sayed Mehdi Hamadani, MD, Hematology, Milwaukee, WI, Froedtert and the Medical College of Wisconsin Froedtert Hospital

Sayed MehdiHussainHamadaniMD

Hematology Milwaukee, WI

Physician

Dr. Hamadani is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Hamadani's full profile

Already have an account?

  • Office

    9200 W Wisconsin Ave
    Division Of Neoplastic Diseases
    Milwaukee, WI 53226
    Phone+1 414-805-6800
    Fax+1 414-805-6805
  • Is this information wrong?

Education & Training

  • Ohio State University Hospital
    Ohio State University HospitalFellowship, Hematology and Medical Oncology, 2006 - 2009
  • University of Oklahoma Health Sciences Center
    University of Oklahoma Health Sciences CenterResidency, Internal Medicine, 2003 - 2006
  • King Edward Medical University
    King Edward Medical UniversityClass of 2001

Certifications & Licensure

  • WI State Medical License
    WI State Medical License 2013 - 2025
  • WV State Medical License
    WV State Medical License 2009 - 2014
  • OH State Medical License
    OH State Medical License 2006 - 2009
  • OK State Medical License
    OK State Medical License 2005 - 2006
  • American Board of Internal Medicine Hematology

Publications & Presentations

PubMed

Abstracts/Posters

  • Outcomes Following Early Relapse in Patients with Mantle Cell Lymphoma
    Mehdi Hamadani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Maintenance Rituximab Improves Outcomes in Mantle Cell Lymphoma Patients Who Respond to Induction Therapy with Bendamustine + Rituximab without Autologous Transplant
    Mehdi Hamadani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Interim Futility Analysis of a Phase 2 Study of Loncastuximab Tesirine, a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients with Relapsed or Refra...
    Mehdi Hamadani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Join now to see all

Lectures

  • Phase I/II Trial of Bendamustine, Ixazomib and Dexamethasone (BID) in Patients (pts.) with Relapsed/Refractory Multiple Myeloma (RRMM) 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Adct-301 (Camidanlumab Tesirine), a Novel Pyrrolobenzodiazepine-Based CD25-Targeting Antibody Drug Conjugate, in a Phase 1 Study of Relapsed/Refractory Non-Hodgkin Lym... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Hospital Affiliations